428
Participants
Start Date
July 31, 2015
Primary Completion Date
November 30, 2018
Study Completion Date
November 30, 2022
MiStent
Primary in situ coronary artery disease patients (all patients enrolled with a maximum of two target lesions in different blood vessels and maximum of 2 stents per lesion. Lesions with reference diameter of 2.5mm-3.5mm (by visual measurement) and with length ≤40mm (by visual measurement).
TIVOLI
Primary in situ coronary artery disease patients (all patients enrolled with a maximum of two target lesions in different blood vessels and maximum of 2 stents per lesion. Lesions with reference diameter of 2.5mm-3.5mm (by visual measurement) and with length ≤40mm (by visual measurement).
The Third Xiangya Hospital of Central South University, Changsha
The First Affiliated Hospital of Baotou University, Baotou
Inner Mongolia People'S Hospital, Hohhot
The First Affiliated Hospital of Inner Mongolia Medical University, Hohhot
The Second Affiliated Hospital of Nanchang University, Nanchang
The First Affiliated Hospital of Xi'An Jiaotong University, Xi'an
Sir Run Run Shaw Hospital School of Medicine, Zhejiang University, Hangzhou
The General Hospital of Shenyang Military Region, Area of Shenyang
Fu Wai Hospital, National Center for Cardiovascular Disease, Beijing
The First Hospital of Jilin University, Changchun
The Second Xiangya Hospital of Central South University, Changsha
The First Hospital of Lanzhou University, Lanzhou
Shanghai Ninth People's Hospital, Shanghai
West China Hospital, Sichuan University, Sichuan
The Second Hospital of Shanxi Medical University, Taiyuan
TEDA International Cardiovascular Hospital, Tianjin
Lead Sponsor
Collaborators (1)
Hefei Life Science Medical Instruments Co. Ltd.
UNKNOWN
Giant Med-Pharma Services Inc.
INDUSTRY
CCRF Consulting Co., Ltd.
OTHER
Micell Technologies
INDUSTRY